In one paragraphArticle in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 72% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors at 5 institutions in 1 country.
George W SmallPharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-7585-7258 Farida S AkhtariBiostatistics and Computational Biology Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
Adrian J GreenDepartment of Biological Sciences, Bioinformatics Research Center, North Carolina State University, Raleigh, NC 27695, USA.ORCID 0000-0001-9429-1838 Tammy M HavenerStructural Genomics Consortium and Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Michael SikesDepartment of Biological Sciences, North Carolina State University, Raleigh, NC 27695, USA.
Ricardo D GonzalezPharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-2549-8138 David M ReifPredictive Toxicology Branch, Division of Translational Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.ORCID 0000-0001-7815-6767 Alison A Motsinger-ReifBiostatistics and Computational Biology Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
Howard L McLeodCenter for Precision Medicine and Functional Genomics, Utah Tech University, 225 South University Ave, St. George, UT 84770, USA.ORCID 0000-0002-9004-9232 Tim WiltshirePharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
University of North Carolina at Chapel Hill · USNational Institute of Environmental Health Sciences · USNorth Carolina State University · USFoundation Medicine (United States)Utah Tech University · US
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5MStatistical Genetics of Dose Response TraitsZIAES103336 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI MOTSINGER-REIF, ALISON · 2019 to 2024
$1.7MNCI NIH HHS P30 CA016086NIH HHS 1UM2AI30836-01
6 · The paper itselfAbstract
Monoclonal antibody (mAb) therapy directed against CD20 is an important tool in the treatment of B cell disorders. However, variable patient response and acquired resistance remain important clinical challenges. To identify genetic factors that may influence sensitivity to treatment, the cytotoxic activity of three CD20 mAbs: rituximab; ofatumumab; and obinutuzumab, were screened in high-throughput assays using 680 ethnically diverse lymphoblastoid cell lines (LCLs) followed by a pharmacogenomic assessment. GWAS analysis identified several novel gene candidates. The most significant SNP, rs58600101, in the gene
Indexed as
Antineoplastic AgentsPharmacogenomic TestingAntibodies, MonoclonalAntigens, CD20HumansPrednisoloneAntibodies, MonoclonalAntigens, CD20Antineoplastic AgentsPrednisoloneCD20 (MS4A1)MKL1 (MRTFA)obinutuzumab (Gazyva®)ofatumumab (Arzerra®, Kesimpta®)rituximab (Rituxan®)TGFB1
Identifiers
PMID37371044
PMCPMC10297299
OpenAlexW4379793150
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390